Douglas Katz MD

• Assistant Professor of Surgery and Pediatrics, Jefferson Medical College,
• Philadelphia, Pennsylvania
• Attending Surgeon, Nemours/Alfred I. duPont
• Hospital for Children, Wilmington, Delaware

Overall survival rates were not significantly improved erectile dysfunction medication with high blood pressure purchase vivanza with american express, however (92% vs 86% erectile dysfunction gluten vivanza 20 mg order with amex, respectively) [127] impotence young males vivanza 20 mg purchase otc. The dose of radiation at the surface of the vaginal apex usually is boosted to 6 erectile dysfunction type of doctor generic vivanza 20 mg buy on-line,000 to 7 erectile dysfunction hormones buy cheap vivanza on line,000 cGy by a variety of techniques. The most frequently reported side effects are gastrointestinal, usually abdominal cramps and diarrhea, although more serious Patients with histologically proven paraaortic node metastases and no other evidence of disease spread outside the pelvis should be treated with extendedfield radiation. The entire pelvis, common iliac lymph nodes, and paraaortic lymph nodes are included within the radiation field. Extendedfield radiotherapy appears to improve survival in patients with endometrial cancer who have positive paraaortic lymph nodes [129, 142]. Fiveyear survival rates of 47% and 43% are reported for patients with surgically confirmed isolated paraaortic lymph node metastases and for those with paraaortic and pelvic lymph node metastases, respectively, using postoperative extended field radiation. A comparison of patients with positive paraaortic nodes treated with megestrol acetate alone versus extendedfield radiation showed that survival rate in patients receiving extendedfield radiation was significantly better: 53% vs 12. In another study of 18 patients with positive paraaortic nodes, 5year survival rates were 67% for those with microscopic nodal disease and 17% with gross nodal disease [144]. Progestins Because most endometrial cancers have both estrogen and progesterone receptors and progestins have been used successfully to treat metastatic endometrial cancer, postoperative adjuvant progestin therapy attempted to reduce the risk of recurrence. This therapy seemed attractive because it provides systemic treatment and has few side effects. Unfortunately, several large randomized, placebocontrolled studies failed to identify a benefit for adjuvant progestin therapy [149, 150]. Patients who received chemotherapy had a 13% improvement in 2year progressionfree survival (50% vs 46%) and an 11% improvement in overall 2year survival (70% vs 59%) compared to patients treated with whole abdomen radiation [148]. Despite this improvement with chemotherapy, the proportion of patients with pelvic failure was 18%, suggesting the need for local control. Endocervical curettage has relatively high falsepositive (50­80%) and falsenegative rates. Three areas must be addressed in any treatment plan: 1) For optimal results, the uterus should be removed in all patients. This method is based on the difficulty in establishing the preoperative diagnosis of cervical involvement in the absence of a gross cervical tumor, the evidence that radiation is equally effective when given after hysterectomy, and the high incidence of extrapelvic disease when the cervix is involved. An extrafascial hysterectomy or modified radical hysterectomy, bilateral salpingooophorectomy, peritoneal washings for cytology, and resection of grossly enlarged lymph nodes are performed. These procedures are followed by appropriate pelvic or extendedfield external and intravaginal radiation, depending on the results of surgical staging. Patients usually have clinical evidence of disease spread to the parametria, pelvic sidewall, or adnexal structures; less frequently, there is spread to the vagina or pelvic peritoneum. In the presence of an adnexal mass, the initial impetus for surgery is to determine the nature of the mass. Surgery is performed to determine the extent of disease and to remove the bulk of the disease if possible. This procedure should include peritoneal washings for cytologic examination, para aortic and pelvic lymphadenectomy, biopsy or excision of any suspicious areas within the peritoneal cavity, and omentectomy and peritoneal biopsies. Except in patients with bulky parametrial disease, hysterectomy and bilateral salpingo oophorectomy should be performed. Despite the small number of patients included in the studies examining cytoreduction, it appears that optimal cytoreduction may be associated with improved survival [159]. Patients who are treated with combined surgery and radiation fare better than patients who receive radiation therapy alone [158]. One objective of surgery and radiation therapy is to achieve local disease control in the pelvis to provide palliative relief of bleeding, discharge, and complications involving the bladder and rectum. Several reports have noted a positive impact of cytoreductive surgery on survival, the median survival being about three times greater with optimal cytoreduction (18­ 34 months vs 8­11 months, respectively) [163­165]. Pelvic exenteration may be considered in the very rare patient in whom disease is limited to the bladder, rectum, or both [166]. FollowUp after Treatment History and physical examination remain the most effective methods of followup in patients treated for endometrial cancer [167­169]. Patients should be examined every 3­6 months during the first 2 or 3 years and every 6­12 months thereafter. Vaginal bleeding is a common symptom consistent with local recurrence; other common symptoms include abdominal and/or pelvic pain, changes in bowel or bladder habits, lethargy, and weight loss. These or related symptoms are reported by 41­83% of patients and more than 80% of recurrences are detected by a combination of physical examination and symptoms. Very few asymptomatic recurrences are detected by vaginal cytology (0­7%) and fewer than 20% of asymptomatic recurrences are detected by annual chest Xray. Because of the low rates of detection of these screening modalities, many gynecologic oncologists have challenged their use [170]. More than 50% of the recurrences develop within 2 years, and about 75% occur within 3 years of initial treatment. The distribution of recurrences is dependent in large part on the type of primary therapy: surgery alone versus surgery plus local or regional radiotherapy. Therefore, after combined surgery and radiotherapy (vaginal or external beam), 70% or more of patients with treatment failures have distant metastases, and most of these patients do not have evidence of local or pelvic recurrence [85]. The most common sites of extrapelvic metastases are lung, abdomen, lymph nodes (aortic, supraclavicular, inguinal), liver, brain, and bone. Patients with isolated vaginal recurrences fare better than those with pelvic recurrences, who in turn have a better chance of cure than those with distant metastases [172]. Patients who initially have well differentiated tumors or who develop recurrent cancer more than 3 years after the primary therapy also tend to have an improved prognosis. Hormonal Therapy Progestins are recommended as initial treatment for all patients with recurrent lowgrade endometrioid tumors with hormone receptorpositive tumors. Radiation therapy, surgery or both should be used whenever feasible for treatment of localized recurrent cancer such as vaginal, pelvic, bone, and peripheral lymph node disease; however, these patients should also be given longterm progestin therapy unless they are known to have a progesteronereceptornegative tumor. Patients with nonlocalized recurrent tumors, especially if progesterone receptors are known to be positive, are candidates for progestin therapy, either megestrol acetate, 80 mg twice daily, or medroxyprogesterone acetate, 50­100 mg three times daily. Higher response rates are observed in patients with welldifferentiated tumors and a longer diseasefree interval. Progestin therapy should be continued for at least 2­3 months before assessing response. If a response is obtained, the progestin should be continued for as long as the disease is static or in remission. Failure to respond to hormonal therapy is an indication for initiation of chemotherapy [173]. Radiation Therapy Radiotherapy is the best treatment option for patients with isolated localregional recurrences [174, 175]. Women with lowvolume disease limited to the pelvis (most of which is contained in the vagina) have the best outcome. Retrospective studies showed complete remission rates after salvage therapy for isolated vaginal relapse to be 40­80% in previously unirradiated patients, compared to 280 Female Reproductive Cancer 10­25% in those who had previously been irradiated [171]. Conversely, for those patients who undergo radiation for pelvic extension of their disease, lower survival rates (0­26%) are reported. Chemotherapy Chemotherapy with a platinum agent and a taxane has become the standard adjuvant treatment setting for advanced endometrial cancer [152]. Individually, the response rates of platinum agents and paclitaxel range from 20 to 36% [176]. In one retrospective study, the overall response rate to combination carboplatin and paclitaxel in patients with either advanced or recurrent endometrial cancer was 43%, but only 5% achieved a complete response [177]. There are no effective single agents for disease recurrence after treatment with firstline platinum/taxane combinations [172]. Surgery A small subset of patients with isolated recurrent endometrial cancer may benefit from surgical intervention. A search for distant recurrences prior to treatment is obligatory as such patients are best treated with chemotherapy. In one small series, upper abdominal disease was found at laparotomy in three (37. Isolated vaginal recurrence in patients who have not received prior pelvic radiation is best treated with external radiation plus some type of brachytherapy. Treatment of patients with pelvic recurrence (generally located on the pelvic sidewall secondary to lymphatic failure) is more complex. Although one study [166] showed no survivors among patients with pelvic recurrences, there is some evidence that a multimodality approach consisting of radiotherapy followed by radical surgical resection and intraoperative radiotherapy may cure some patients, albeit with a higher complication rate [179]. Of 36 patients with isolated central pelvic recurrence who underwent pelvic exenteration for recurrent endometrial carcinoma, 75% died of their cancer within 1 year of operation, and only 14% were alive after 5 years [180]. Estrogen Replacement Therapy after Treatment Most endometrial cancers are associated with excess estrogen exposure, calling into question the appropriateness of estrogen therapy for women with a history of endometrial cancer following hysterectomy and bilateral salpingooophorectomy. Several nonrandomized and cohort retrospective studies have reported that estrogen therapy appears safe with no documented increase in the risk of recurrence following surgical treatment for endometrial carcinoma [181­183]. Some investigations reported higher intercurrent death rates, such as from myocardial infarction, in the group in which estrogen was withheld [181, 184]. The American College of Obstetricians and Gynecologists issued a committee opinion recommending that providers should take into consideration prognostic indicators, such as depth of invasion, grade, and stage when deciding to administer estrogen therapy to these patients [185]. For women who decline systemic estrogen therapy, symptoms of vaginal dryness and dyspareunia may be judiciously treated with topical estrogen alone. Symptomatic relief of hot flashes can be achieved by prescribing progestins or nonhormonal agents such as clonidine and venlafaxine. There is an increased incidence of uterine sarcomas after radiation therapy to the pelvis for either carcinoma of the cervix or a benign condition. The relative risk of uterine sarcoma after pelvic radiotherapy is estimated to be 5. Uterine sarcomas are, in general, the most malignant group of uterine tumors and differ from endometrial cancer with regard to diagnosis, clinical behavior, pattern of spread, and management. Classification and Staging the two most common histologic types of uterine sarcoma are leiomyosarcoma (1. Uterine Corpus Cancer 281 Endometrial Stromal Tumors Stromal tumors occur primarily in perimenopausal and postmenopausal women. There is no apparent relationship to parity, associated disease, or prior pelvic radiotherapy. The most frequent symptom is abnormal uterine bleeding; abdominal pain and pressure caused by an enlarging pelvic mass occur less often, and some patients do not have symptoms. Pelvic examination usually reveals regular or irregular uterine enlargement, sometimes associated with rubbery parametrial induration. The diagnosis may be determined by endometrial biopsy, but the usual preoperative diagnosis is uterine leiomyoma. Endometrial stromal tumors are composed of cells with morphological and histochemical features resembling normal endometrial stroma. They are divided into three types: endometrial stromal nodule, lowgrade endometrial stromal sarcoma, and highgrade endometrial stromal sarcoma. Additionally, undifferentiated uterine sarcoma is grouped in the same category as endometrial stromal sarcomas [18, 68]. These tumors should be considered benign because there are no recurrences or tumor associated deaths reported after surgery [190, 191]. The distinction between an endometrial stromal nodule and lowgrade endometrial stromal sarcoma is based on prominent myometrial, lymphatic, and in some cases venous invasion. Recurrences typically occur late, and local recurrence is more common than distant metastases [192, 193]. Optimum initial therapy for patients with lowgrade endometrial stromal sarcoma consists of surgical excision of all grossly detectable tumor. The fallopian tubes and ovaries should usually be removed as well because of the propensity for tumor extension into the parametria, broad ligaments, and adnexal structures and the possible stimulating effect of estrogen on tumor cells if the ovaries are retained. The relatively low rate of lymph node metastasis in the absences of gross lymph node involvement or extrauterine disease suggests that a lymph node sampling or lymphadenectomy is not necessary [194]. Postoperative pelvic radiation is recommended for inadequately excised or locally recurrent pelvic disease. Recurrence occurs in almost 50% of cases at an average interval of 5 years after initial therapy. Owing to the indolent nature of the disease, cytotoxic chemotherapy is unlikely to be beneficial; however, hormonal treatment with progestins appears to have some efficacy, with reported response rates close to 50%. Prolonged survival and cure are common even after development of recurrent or metastatic disease. Highgrade endometrial stromal sarcoma and undifferentiated uterine sarcoma are highly malignant neoplasms although prognosis is poorer for the latter. Undifferentiated uterine sarcomas, by definition, lack recognizable morphological or immunohistochemical evidence of smooth muscle differentiation or endometrial stromal differentiation [68]. This tumor has a much more aggressive clinical course and poorer prognosis than lowgrade endometrial stromal sarcoma [187, 191­193]. Treatment of highgrade endometrial stromal sarcoma and undifferentiated uterine sarcoma should consist of total hysterectomy and bilateral salpingooophorectomy. The poor therapeutic results suggest that radiation therapy, chemotherapy, or both should be used in combination with surgery. These tumors, unlike lowgrade endometrial stromal sarcoma, are not responsive to progestin therapy. Leiomoyosarcoma the median age for women with leiomyosarcoma is 43­53 years, and premenopausal women have a better chance of survival. This malignancy has no relationship with parity, and the incidence of associated disease is not as high as in carcinosarcoma or endometrial adenocarcinoma. African American women have a higher incidence and a poorer prognosis than women of other races. A history of prior pelvic radiation therapy can be elicited in about 4% of patients with leiomyosarcoma.

Bimanual rectovaginal examination should be performed specifically to evaluate the uterus for size and mobility erectile dysfunction treatment edmonton buy generic vivanza 20 mg on line, the adnexa for masses erectile dysfunction gay buy 20 mg vivanza with mastercard, the parametria for induration erectile dysfunction specialist doctor buy cheap vivanza 20 mg on-line, and the culdesac for nodularity impotence restriction rings purchase genuine vivanza. Chest imaging should be performed to exclude pulmonary metastasis and to evaluate the cardiorespiratory status of the patient erectile dysfunction doctors in san fernando valley order generic vivanza from india, and complete blood and platelet counts should be done. Other preoperative studies may include electrocardiography and serum chemistries (including renal and liver function tests). Studies such as cystoscopy, colonoscopy, and barium enema are not indicated unless dictated by patient symptoms, physical findings, or other laboratory tests [73]. This information may be of use in planning the surgical procedure with regard to whether lymph node sampling should be undertaken. With improvements in preoperative and postoperative care, anesthesia administration, and surgical techniques, almost all patients are medically suitable for operative therapy. A small percentage of patients will not be candidates for surgical staging because of gross cervical involvement, parametrial spread, invasion of the bladder or rectum, or distant metastasis. Surgical Staging Surgical staging for endometrial cancer, consists of hysterectomy, removal of the adnexal structures, peritoneal cytology, and lymph node sampling where appropriate (Table 20. Surgical staging not only identifies most patients with extrauterine disease, but also identifies patients with uterine risk factors for recurrence, including large tumor size, deep myometrial invasion, lymphvascular space invasion, and cervical extension, thereby allowing for a more informed approach to postoperative adjuvant therapy. Lymph node dissections as part of surgical staging is not required in patients assessed intraoperatively to be at low risk for lymph node metastasis (<2 cm, grade 1­2 tumors with superficial myometrial invasion), whereas systematic lymph node dissection should be performed in most other patients with endometrial cancer (Table 20. Surgicalpathologic findings Histology Adenocarcinoma Adenosquamous Other (papillary serous, clear cell) Grade 1 2 3 Myometrial invasion None Inner third Middle third Outer third Positive peritoneal cytology Lymphvascular space invasion Isthmic involvement Adnexal involvement Pelvic lymph node metastasis Aortic lymph node metastasis Other extrauterine metastasis Source: adapted from Creasman et al. Prognostic Variables Although disease stage is the most significant variable affecting survival, a number of other individual prognostic factors for disease recurrence or survival are known. Age In general, younger women with endometrial cancer have a better prognosis than older women. Increased risk for recurrence in older patients is related to a higher incidence of grade 3 tumors or unfavorable histologic subtypes; however, increasing patient age has been shown to be independently associated with disease recurrence. In one study, for every 1year increase in age, the estimated rate of recurrence increased 7% [82]. Histologic Type Nonendometrioid histologic subtypes carry an increased risk for recurrence and distant spread [83, 84]. Histologic Grade better defined an intermediate risk group for lymph node metastasis. Overall, these patients had a 10% risk for lymph node metastasis, but there were no nodal metastases associated with tumors 2 cm or smaller, compared with 18% when tumors were larger than 2 cm. Fiveyear survival rates were 98% for patients with tumors 2 cm or smaller, 84% for patients with tumors larger than 2 cm, and 64% for patients with tumors involving the whole uterine cavity [89, 91]. Hormone Receptor Status Histologic grade of the endometrial tumor is strongly associated with prognosis (Table 20. Patients with grade 3 tumors were more than five times more likely to have a recurrence than were patients with grades 1 and 2 tumors. The 5year diseasefree survival rates for patients with grades 1 and 2 tumors were 92% and 86%, respectively, compared with 64% for patients with grade 3 tumors [82]. Tumor Size Patients whose carcinomas are positive for estrogen receptor and/or progesterone receptors have longer survival times than patients whose carcinomas lack these receptors. Even patients with metastases have an improved prognosis with receptor positive tumors [92­94]. Progesterone receptor levels appear to be stronger predictors of survival than estrogen receptor levels, and the higher absolute levels of the receptors the better the prognosis. Myometrial Invasion Tumor size is a significant prognostic factor for lymph node metastasis and survival in patients with endometrial cancer [88, 89]. One report determined tumor size in 142 patients with clinical stage I endometrial cancer and found lymph node metastasis in 4% of patients with tumors 2 cm or smaller, in 15% of patients with tumors larger than 2 cm, and in 35% of patients with tumors involving the entire uterine cavity [90]. Tumor size Because access to the lymphatic system increases as cancer invades into the outer onehalf of the myometrium, increasing depth of invasion is associated with increasing likelihood of extrauterine spread, including lymph node metastasis and recurrence [87, 95, 96]. Of patients without demonstrable myometrial invasion, only 1% had pelvic lymph node metastasis, compared with patients with outer onethird myometrial 274 Female Reproductive Cancer invasion of whom 25% had pelvic and 17% had aortic lymph node metastases. Deep myometrial invasion is the strongest predictor of hematogenous recurrence [97]. Patients with noninvasive or superficially invasive tumors have an 80­90% 5year survival rate, whereas those with deeply invasive tumors have a 60% survival rate [98, 99]. Failures were observed outside the abdomen in 100% of patients with full thickness myometrial invasion or uterine serosal invasion, and in 20­25% of cases in the presence of isolated adnexal invasion [85, 109]. Isthmus and Cervix Extension the location of the tumor within the uterus is important. Involvement of the uterine isthmus, cervix or both is associated with an increased risk for extrauterine disease, lymph node metastasis, and recurrence. One study reported that if the fundus of the uterus alone was involved with tumor, there was a 13% recurrence rate, whereas if the lower uterine segment or cervix was involved with occult tumor, there was a 44% recurrence rate [84]. Peritoneal Cytology Lymph node metastasis is a very important prognostic factor in clinical earlystage endometrial cancer. Of patients with clinical stage I disease, about 10% will have pelvic and 6% will have para aortic lymph node metastases. Patients with lymph node metastases have almost a sixfold higher likelihood of developing recurrent cancer than patients without lymph node metastasis. One study reported a recurrence rate of 48% among patients with positive pelvic nodes, including 45% with positive pelvic nodes and 64% with positive aortic nodes, compared to 8% for patients with negative nodes. The 5year diseasefree survival rate for patients with lymph node metastases was 54% compared to 90% for patients without lymph metastases [104]. One series examined patients with lymph node metastases in addition to other extrauterine sites of disease (vagina, uterine serosa, positive peritoneal cytology, adnexal invasion). The recurrence rates were 67% (41% extranodal) for those with lymphatic dissemination versus 32% (5% extranodal) for those with other sites of extrauterine disease spread [105]. Intraperitoneal Metastases Reports regarding the prognostic relevance of positive peritoneal cytology have been inconsistent, due at least in part to differences in use of multivariate analyses. Patients with positive peritoneal cytology as the only site of extrauterine disease. These patients have an associated 5year survival of 98­ 100% even when not treated with adjuvant therapy [104­106]. On the other hand, patients with positive cytology in addition to poor prognostic factors demonstrate a high rate (47%) of distant extraabdominal failure and may potentially benefit from systemic chemotherapy. Positive peritoneal cytology seems to have an adverse effect on survival only if the endometrial cancer has spread to the adnexa, peritoneum, or lymph nodes, not if the disease is otherwise confined to the uterus [105, 107, 108]. Gross intraperitoneal spread is highly associated with lymph node metastases; one study noted that 51% of patients with intraperitoneal tumor had positive lymph nodes, whereas only 7% of patients without gross peritoneal spread had positive nodes [86]. Extrauterine spread other than lymph node metastasis is significantly associated with tumor recurrence. Another study found that 50% of patients with extrauterine disease developed recurrence, compared with 11% of patients without extrauterine disease. The 5year diseasefree survival rate for patients with nonlymphatic extrauterine disease was 50%, compared with 88% in other patients [104]. Surgical Treatment the most common current protocol for surgical management of endometrial cancer includes peritoneal cytology, hysterectomy, bilateral salpingooophorectomy, and surgical staging. In patients with nonendometrioid cancer, omentectomy and peritoneal biopsies may be performed. One series described treatment of all patients with serosal or adnexal Uterine Corpus Cancer 275 myometrial invasion, and the presence of extrauterine disease determined during the surgery (see Surgical Staging). Vaginal Hysterectomy Minimally Invasive Surgery: Laparoscopic or Robotic Vaginal hysterectomy may be considered for selected patients who are extremely obese and have a poor medical status or for patients with extensive uterovaginal prolapse. Vaginal hysterectomy with bilateral salpingooophorectomy may be considered adequate treatment for patients with lowrisk tumors (endometrioid histology, grade 1 or 2, <50% myometrial invasion, and tumor diameter <2 cm). Vaginal hysterectomy is particularly suitable for patients who are at low risk for extrauterine spread of disease. In one report, a 94% survival rate was observed among 56 patients with clinical stage I (mostly grade 1) endometrial carcinoma treated by vaginal hysterectomy, with or without postoperative radiotherapy (mostly brachytherapy) [113]. Vaginal hysterectomy is preferable to radiation therapy alone, but should be reserved for specific patients. Advances in endoscopic technologies and power sources have allowed application of laparoscopic/robotic approaches to the management of endometrial cancer [114­116]. Consistent with early reports, patients randomized to laparoscopy had shorter hospital stays (52% more than 2 days vs 94% in the laparotomy group), less blood loss, and fewer postoperative complications (14% vs 21%). The rate of intraoperative complications was similar, and the operative time was longer in the laparoscopy cohort. There was no difference in lymph node counts, and stage distribution was identical between groups. A followup qualityoflife investigation of the same cohorts revealed better physical functioning, better body image, less pain and its interference with quality of life, and an earlier resumption of normal activities and return to work over the 6week recovery period in the laparoscopic group [118]. Of concern was the 24% rate of conversion in the laparoscopic cohort; only 4% were converted because of advanced disease. Risk factors: age >60 years, grade 2/3, lymphvascular space invasion, outer half myometrial invasion, histologic subtype serous or clear cell. Robotic Surgery Roboticassisted surgery has gained popularity for endometrial cancer treatment. In 2010, a systematic review summarized most of the comparative studies on endometrial cancer at that time. The perioperative outcomes were similar for robotic and laparoscopic procedures with decreased blood loss and shorter hospital stays but longer operative times compared with laparotomy. Radiation Therapy as Primary Treatment 2) Hematogenous: deep myometrial invasion is the strongest predictor of hematogenous recurrence (>50% for all stages and >66% for stage I) [97, 131]. Patients with the risk factors previously discussed account for 35% of all the overall population with endometrial cancer, but 89% of the observed hematogenous, lymphatic, and peritoneal relapses. Importantly, 46% of the patients considered at risk subsequently experience a recurrence in one or more of the three sites, compared with only 2% of patients not judged to be at risk based on these criteria (P <0. The identification of subgroups of patients at risk for the different patterns of recurrence would allow postoperative treatment targeted to the predicted areas of tumor dissemination. Patients at risk for hematogenous or peritoneal recurrence would potentially benefit from systemic cytotoxic treatment, whereas patients at risk for lymphatic or vaginal recurrence would potentially benefit from radiation treatment directed to areas at risk. Postoperative Treatment Observation Primary surgery followed by individualized radiation therapy is the most widely accepted treatment for earlystage endometrial cancers. However, about 5­15% of endometrial cancer patients have severe medical conditions that render them unsuitable for surgery [122]. Several series show that radiotherapy is effective treatment for patients with inoperable endometrial cancer [123­125]. Although radiation alone can produce excellent survival and local control, it should be considered for definitive treatment only if the operative risk is estimated to exceed the 10­15% risk for uterine recurrence that is expected with radiation treatment alone. Patterns of Metastatic Dissemination: Implications for Postoperative DiseaseBased Adjuvant Treatment Approximately one of every three women who dies of endometrial cancer was considered to have early locoregional disease at primary diagnosis. Most treatment failures and the accompanying compromised longevity probably result from failure to recognize sites of occult extrauterine dissemination at primary diagnosis. Traditional postoperative therapy (modalitybased) for highrisk endometrial cancer is externalbeam radiotherapy that is frequently supplemented with vaginal brachytherapy [126]. This approach improves local control but not survival in earlystage disease [127­129]. Understanding the different pathways of metastatic dissemination of endometrial cancer and their predictive factors allows the development of an individualized model for targetbased therapeutic approaches to the predicted site(s) of failure. The natural history of epithelial corpus cancer includes four potential routes of metastasis: (i) contiguous extension (mainly to the vagina), (ii) hematogenous dissemination, (iii) lymphatic embolization, and (iv) exfoliation with intraperitoneal spread. Independent pathologic risk factors predictive of the four routes of metastatic spread are: 1) Contiguous extension: histologic grade 3 and lymphovascular space invasion are proven predictors of vaginal relapse in stage I endometrial cancer [130]. Patients with grade 1 and 2 lesions, with no or minimal myometrial invasion, and without any of the above risk factors have an excellent prognosis (diseasefree 5year survival rate approaching 100%) and require no postoperative therapy [85, 132, 133]. There was a higher rate of nonvaginal pelvic relapse in the brachytherapy group (3. However, the absolute difference was small and Uterine Corpus Cancer 277 there was no difference in overall survival [139]. External Pelvic Radiation complications such as bleeding, proctitis, bowel obstruction, and fistula can occur and may require surgical correction. The urinary system may be affected in the form of hematuria, cystitis, or fistula. The overall complication rate ranges from 25 to 40%; and the rate of serious complications requiring surgical intervention is about 1. Externalbeam pelvic radiation does not appear to impact survival in patients with highrisk stage I endometrial cancer. Patients with extrauterine pelvic disease, including adnexal spread, parametrial involvement, and pelvic lymph node metastases, in the absence of extrapelvic disease, are most likely to benefit from postoperative pelvic radiation. ExtendedField Radiation Radiation therapy traditionally was suggested to patients who were deemed to have an intermediate or high risk of recurrence, according to grade and depth of myometrial invasion. Localregional recurrences developed in 14% of the surgery group, compared with 4% of the postoperative pelvic radiation group. The 5year survival rates were not different between the two groups (85% vs 81%, respectively) [129]. After 2 years, the cumulative recurrence rate was 12% in the group with no postoperative treatment compared with 3% in the group that received pelvic radiation. The incidence of sarcomatous change in benign uterine leiomyomas is reported to be between 0. Survival rates for patients with uterine leiomyosarcoma range from 20 to 63% (mean 47%) [3, 196­198]. Presenting symptoms, which are of short duration (mean 6 months) and not specific to the disease, include vaginal bleeding, pelvic pain or pressure, and awareness of an abdominopelvic mass.

Neurofibromas in these patients have abnormal cells with mutations of chromosome 17q11 high cholesterol causes erectile dysfunction vivanza 20 mg on-line. Malignant Peripheral Nerve Sheath Tumor Fortunately uncommon doctor's advice on erectile dysfunction purchase vivanza 20 mg, malignant lesions of peripheral nerves are most commonly represented by malignant peripheral nerve sheath tumors impotence treatment after prostate surgery generic vivanza 20 mg free shipping. These tumors may have poorly defined margins with an infiltrative nature making surgical resection for cure impossible impotence vs infertile buy cheap vivanza 20 mg on-line. Symptoms are location specific and include pulsating tinnitus erectile dysfunction treatment san francisco vivanza 20 mg visa, otorrhea, facial nerve dysfunction, and difficulty swallowing. Therapy can include surgery; however this can be associated with high rates of morbidity and mortality. Studies of stereotactic radiosurgery have shown local tumor control in up to 100% of patients, with stable tumor volume in 60% and tumor shrinkage achieved in 40% of cases. Neurofibromas contain cells with features of Schwann cells, fibroblasts, and perineural cells. Tumors of both types are benign and can be cured surgically if they are a component of a noncritical nerve or relatively separate from fibers of a highfunction nerve projection. These lesions are located in the cerebellopontine angle or in the internal acoustic canal. If the tumors grow to be large, they may compress the cerebellum and brainstem, causing gait ataxia and hydrocephalus. Numbness in the face from involvement of the trigeminal nerve and facial paralysis from involvement of the facial nerve also can be features. Often, they are located in and expand the internal auditory meatus, a deformity not usually caused by meningiomas [136]. Perineural Tumor Invasion Tumors of the skin, pancreas, colon and rectum, prostate, head and neck, biliary tract, and stomach, though not primarily neural in nature, are quite capable of invading the peripheral nervous system adjacent to them and utilizing the nerves as a route for distant spread [140]. Symptoms include pain or loss of sensation or motor function in the distribution of the involved nerve. In surgical specimens it is important for pathologists to pay attention to involved and adjacent nerve tissue for this process as it may provide a clue to nascent distant tumor spread [140]. Cranially, this process can be important with cutaneous squamous cell carcinoma finding its way to the cavernous sinus along branches of the trigeminal nerve. By this and other neural routes to the central nervous system leptomeningeal carcinomatosis can develop with all of its devastating effects [141]. Adamantinomatous tumors typically occur in children and have cystic and solid components containing cholesterolrich fluid and calcifications. Papillary craniopharyngiomas occur mainly in adults and are solid masses without calcifications or cholesterol deposits. Genetic alterations in chromosomes 2 and 12 have been identified and malignant transformation has rarely been reported [147­149]. Most are suprasellar but they can also occur in intrasellar or ectopic cranial sites [150­154]. Symptoms include visual disturbances, hypothalamic­pituitary dysfunction, behavioral problems, and hydrocephalus [155­157]. Rarely, intratumoral hemorrhage or cyst rupture can result in aseptic meningitis or spontaneous nasopharyngeal drainage [158­160]. Complete surgical resection is the desirable option for craniopharyngioma patients. However, in many cases complete surgical resection cannot be achieved safely [162]. Use of proton radiotherapy has been reported in an effort to maximize treatment effect [173, 174]. Intracavitary radiotherapy with colloidal chromic phosphate or yttrium 90 has also been performed [175, 176]. Chordomas Chordomas of the skull base account for approximately 1­4% of primary bone tumors. They are considered nonmalignant tumors but are locally destructive in the skull base and tend to recur despite treatment. Chordomas cause compression and destruction of surrounding anatomic structures in the skull base. Patients can present with headache, neck pain, diplopia, hydrocephalus, sensorimotor deficits, and endocrine abnormalities due to pituitary dysfunction. On T2weighted images, they have a hyperintense appearance due to high fluid content, calcifications, and their bony involvement. However, gross total removal cannot be achieved in many cases due to neurovascular involvement. Management of chordomas includes surgical resection followed by adjuvant radiation therapy, as chemotherapy is limited and generally ineffective [143]. Adjuvant proton beam radiotherapy is used for residual chordomas since high doses of radiation can be prescribed to the tumor site with minimal Epidermoid and Dermoid Cysts Epidermoid and dermoid cysts are slowgrowing benign lesions accounting for approximately 0. Dermoid cysts contain elements of the dermis such as hair follicles and apocrine, sebaceous, and sweat glands whose symptoms are related to tumor location. Symptomatic epidermoid or dermoid cysts should be approached surgically though this may not be curative [180­185]. Most of them contain gelatinous viscous material and are located in the anterior third ventricle. These Central Nervous System and Peripheral Nerves 589 may cause obstructive hydrocephalus, positional headache, nausea and vomiting, dizziness, memory difficulties, and syncopal events [186, 187]. Symptomatic lesions should undergo surgical removal by endoscopic or microsurgery techniques [188­190]. The relationship between hormones and meningioma risk has been demonstrated [191, 192]. The majority of benign meningiomas consistently express progesterone receptors and may also express androgen and estrogen receptors [193]. Meningiomas also express a high density of somatostatin receptors, as well as dopamine (D1) and glucocorticoid receptors. The primary chromosomal abnormality in meningiomas appears to be monosomy or deletion of chromosome 22 [194­196]. Atypical and malignant meningiomas are much less common and are associated with a higher rate of recurrence and aggressive growth. A meningioma can take the shape of the underlying bone and in this case is called "meningioma en plaque. Immunohistological markers positive in meningiomas are epithelial membrane antigen, vimentin, laminin, fibronectin, keratin, and S100. Many meningiomas grow very slowly, thus remaining asymptomatic during life, and are found incidentally. Symptomatic meningiomas commonly present as an enlarging mass that eventually leads to compression of surrounding brain structures. Most meningiomas are located intracranially and of these about 90% are supratentorial. The signs and symptoms of patients with meningiomas at presentation are slow in onset, as well as variable depending on tumor location [197]. The most common presenting symptoms are newonset headache, personality changes, and hemiparesis, followed by seizures, visual impairment, ataxia, and aphasia [198]. Symptoms due to increased intracranial pressure may also occur with larger tumors. They generally enhance intensely but with variable patterns dependent on location and relationship to the surrounding tissue and bone. Meningiomas express somatostatin receptors, permitting the use of somatostatin receptor scintigraphy using octreotide [199]. Surgically accessible tumors in patients who are considered good candidates should undergo tumor resection. The goal of surgery is total removal including the dural attachment, as the completeness of surgical resection is an important prognostic factor [200]. Gross total removal alone is considered definitive treatment for grade I meningiomas [201]. Subtotal surgical removal along with aggressive pathologic features, such as dural sinus invasion or brain infiltration, is associated with higher recurrence rates. Hemangiopericytoma/Solitary Fibrous Tumor Meningeal hemangiopericytoma is a malignant neoplasm that originates from meningeal capillary pericytes. Its molecular and genetic profile, and its biologic behavior, are similar to a dural based sarcoma [217]. Hemangiopericytomas constitute approximately 3% of meningeal tumors and unlike meningiomas are more common in males. Hemangiopericytomas can be misdiagnosed as meningiomas but are more rapidly growing. Headaches and focal neurological signs related to the tumor location are the most common initial symptoms with rare spontaneous hemorrhages being described [218, 219]. Surgical resection is considered the primary modality treatment for hemangiopericytoma [221]. Extraneural metastasis should be treated aggressively with a multimodal approach [223, 224]. They are more frequently located in the pituitary stalk region, brainstem, cerebellum, and spinal cord [227]. Clinical symptoms of hemangioblastomas are due to mass effect and depend on their anatomic location [228­230]. Hemangioblastomas show intense enhancement on T1 weighted images after gadolinium administration, due to the fact that they are highly vascular tumors. Peritumoral edema and cysts, which are frequently associated with hemangioblastomas, can be detected on T2weighted images. Peritumoral cyst formation is a common finding in the majority of hemangioblastomas [231]. In these patients, surgery is required both to relieve the symptoms and provide a definitive diagnosis. The treatment modality of choice for hemangioblastoma is complete resection, which is curative and possible for most hemangioblastomas [228­230]. Extradural (55%) Metastasis (majority) Chordoma Osteoid osteoma Osteoblastoma Aneurysmal bone cyst Chondrosarcoma Osteochondroma Hemangioma Giant cell tumors Plasmacytoma/multiple myeloma Eosinophilic granuloma Ewing sarcoma Intradural extramedullary (40%) Meningioma and schwannoma (45%) Neurofibroma Lipoma Schwannoma Hemangiopericytoma Paraganglioma Metastasis Intramedullary (5%) Astrocytoma and ependymoma (90%) Epidermoid Dermoid Hemangioblastoma Lipoma Ganglioglioma Metastasis (rare, less than 2%) Primary Intraspinal Tumors General Considerations Spinal metastases make up the vast majority of neoplasms involving the spine. In fact, up to twothirds of patients with systemic cancer will have spine metastasis on post mortem examination [235]. This collection of tumors is very heterogeneous and can be divided into three categories based on location relative to the dura and spinal cord: extradural (55%), intradural extramedullary (40%), and intramedullary (5%) (Table 40. Clinical Findings Back pain, although not specific to neoplasms, is the cardinal symptom of spinal tumors and is the presenting symptom in over 80% of all primary spinal tumors [235]. A detailed history and physical examination will help filter out those patients who require further workup. Pain associated with a spinal tumor is typically dull, aching, progressive, and localized over the involved vertebral level. If there is nerve root compression, these patients usually experience pain radiating into the arm, around the chest or abdomen, or down the leg. Unlike pain associated with degenerative disease, tumor pain is frequently exacerbated by bed rest and partly relieved by standing or activity. Coughing, sneezing, and other Valsalva maneuvers, which increase intraspinal pressure, exacerbate the tumor pain. A complete physical and neurologic examination is essential for any patient suspected of having a spinal tumor. The general physical examination should focus on assessing for signs of systemic malignancy. Upper motor neuron signs include spasticity, weakness, hyperreflexia, and extensor plantar responses and are present below the level of cord compression from disruption of the cortical Central Nervous System and Peripheral Nerves 591 spinal tract. Lower motor signs include atrophy, fasciculations, and hyporeflexia and are evident at the involved spinal level only from anterior horn or nerve root compression. Patients presenting with acute or rapidly progressing neurologic deficits require emergent workup. Cauda equina syndrome is caused by compression of the lumbar cauda equina and typically presents with urinary retention, diminished anal sphincter tone, "saddle anesthesia," significant asymmetric motor weakness, lower back pain, and sciatica. In addition, spinal masses may be palpable if they extend into the posterior elements, and they can cause significant deformity from vertebral fractures. It is essential to palpate the region(s) of concern and assess for scoliosis or kyphosis. Frequently, the physical examination will provide enough clues to localize potential lesions and direct imaging [235]. The regions scanned along the neuroaxis are dependent upon the initial history and physical examination. If lesions are discovered, imaging of the entire neuroaxis is often warranted to rule out metastasis. Myelography is contraindicated in patients who are coagulopathic, allergic to contrast agents, or have hydrocephalus. Unfortunately, as many as 14% of patients with spinal cord compression deteriorate neurologically after lumbar myelography [235]. When an abnormality is discovered on imaging, a histologic diagnosis is essential. The location of the tumor relative to the dura and spinal cord can help guide the differential diagnosis. For extradural lesions, one should first search for signs of systemic disease since metastases are most prevalent. If no systemic disease is discovered for sampling, spinal tissue diagnosis is ultimately required and can be made through either a percutaneous imageguided needle biopsy or open surgical biopsy. Lesions extending away from the spinal canal are optimal candidates for needle biopsy; however, an open biopsy allows for concomitant decompression and stabilization if warranted. Treatment Given the heterogeneity of primary spinal cord tumors, there is no single treatment algorithm. Surgery is the first line of therapy for the majority of symptomatic primary spine tumors.

Therapyrelated toxicity was primarily hematologic and gastrointestinal erectile dysfunction laser treatment discount vivanza 20 mg buy on-line, with one treatmentrelated septic death erectile dysfunction quick natural remedies 20 mg vivanza purchase free shipping. Quality of life measures and serious adverse events were similar between the two treatment arms [68] viagra causes erectile dysfunction order 20 mg vivanza visa. Pheochromocytoma Systemic chemotherapy has been utilized for several decades erectile dysfunction hand pump generic vivanza 20 mg line, with some antitumor activity reported impotence nutrition buy vivanza 20 mg overnight delivery. The most commonly used agents are cyclophosphamide, doxorubicin, vincristine, and dacarbazine. The rarity of this entity has precluded prospective assessment of the role of chemotherapy [40]. Sunitinib was administered in a schedule of 50 mg/ day for 4 weeks on and 2 weeks off. Toxicities including thrombocytopenia, mucositis, hypercholesterolemia, hypertriglyceridemia, and hyperglycemia were common. Pheochromocytoma Limited reports in the literature demonstrate some antitumor activity with sunitinib used in the conventional dose and schedule of this agent. Two prospective phase 2 trials have been launched in North America testing the activity of sunitinib and pazopanib respectively. A larger randomized doubleblind phase 2 trial of sunitinib has been activated in Europe [40]. A paradigm to conduct novel agent trials that focus on the target, not the underlying histology, is in the early stages. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. Management of patients with adrenal cancer: recommendations of an international consensus conference. Current update on cytogenetics, taxonomy,diagnosis, and management of adrenocortical carcinoma: what radiologists should know. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Beckwith Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisolsecreting tumors in a series of 202 consecutive patients. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, highvolume center experience. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Longterm survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Lowdose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Current and future medical therapy, and the molecular features of adrenocortical cancer. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Pituitary adenomas are identified in 20% of the general population at autopsy and 10­20% incidentally by brain imaging [1]. They are classified into nonfunctioning and functioning pituitary adenomas based on hormonal activity. In contrast to most other intracranial neoplasms, the White to Black incidence rate ratio for pituitary tumors is 0. The most frequent functioning types of pituitary tumors are prolactinomas, which represent 35% of all pituitary tumors. Primary pituitary carcinomas are extraordinarily rare, with an incidence rate of 0. Metastatic lesions of breast and lung cancers in the sellar region are rare, representing only 1. Allcause mortality is increased in patients with pituitary adenomas, especially from vascular diseases. Patients with acromegaly have mortality 2­3 times above the general population from cardiovascular and respiratory causes and possibly malignant diseases. Confounding factors include hypopituitarism associated with large adenomas, surgery, and radiation therapy [4]. Cushing disease leads to more than double mortality risk from macrovascular diseases, uncontrolled diabetes mellitus, and infections [5]. Biochemical control improves survival, which becomes similar to the general population. Patients with craniopharyngiomas have mortality 3­5 times above the general population. In pituitary carcinomas prognosis is poor with survival of only a few months or 1­2 years despite surgery, radiation, and chemotherapy [7]. Conventional highdose external beam radiation administered for pituitary tumors has been associated with increased cerebrovascular events, but is no longer recommended today. Even with lowerdose conformal radiation, some degree of hypopituitarism may occur in up to 50% patients. Neoplastic Benign2 Pituitary adenoma Craniopharyngioma Gangliocytoma/ganglioglioma Granular cell tumor Meningioma Schwannoma Chordoma Vascular and mesenchymal tumors Malignant Pituitary carcinoma Gliomas Germ cell tumor Lymphoma/leukemia/Langerhans cell histiocytosis Vascular and mesenchymal tumors Metastases Miscellaneous (salivary gland lesions, melanoma, etc. Familial Pituitary Adenomas Most pituitary adenomas are sporadic, although familial predisposition is rarely encountered. Currently, there are no known measures to prevent the development of pituitary adenomas. Etiology and Risk Factors Pathogenesis involves a combination of genetic events, epigenetic silencing of tumor suppressors, oncogenic factors, hormone stimulation, and growth factors. However, the extraordinary cases of pituitary adenoma progression into malignancy may involve a different clone profile in the metastasis and primary tumor [8]. Gene expression studies have identified unique and specific molecular markers for different types of pituitary adenomas. The folate receptor (gp38), a glycosylphosphatidylinositol linked membrane protein that initiates cellular accumulation of 5methyltetrahydrofolic acid in epithelial cells, is preferentially expressed in nonfunctioning adenomas. Folic acid is an essential vitamin and a precursor for cofactors that regulate metabolism and it plays an integral role in cellular growth and development. Pituitary adenomas arise from cells of the anterior pituitary gland and are characterized by immunohistochemistry based on hormone content as somatotroph, lactotroph, thyrotroph, gonadotroph, or nullcell. Clinical­pathological classification takes into account both 544 Endocrine Cancers pathology and endocrine phenotype. On the other hand, functioning gonadotropinomas that cause elevated plasma levels of gonadotrophs and gonadal hormones are extremely rare. Atypical pituitary adenomas are usually macroadenomas invasive at the time of diagnosis, but longterm studies are needed to clarify whether they have a worse prognosis than the remainder of the adenomas [14,15]. Pituitary carcinomas are diagnosed based on subarachnoid, brain, or systemic spread, usually to the liver or bone [3]. The only pituitary hormone potentially mildly elevated is prolactin, due to pituitary stalk compression and diminished inhibitory dopaminergic tone. Immunohistochemical analysis of incidentalomas shows that the majority are nonfunctioning gonadotroph adenomas. Pituitary incidentaloma patients should undergo evaluation for hormone excess (insulinlike growth factor 1 and prolactin level) and hormone deficiencies. Diagnosis of Prolactinomas Patients with prolactinomas present with clinical manifestations related to hormone excess with or without mass effect symptoms. Hyperprolactinemia leads to gonadal inhibition (hypogonadism) and sometimes galactorrhea. Premenopausal women usually present with irregular periods, amenorrhea, infertility, and galactorrhea and harbor microadenomas. Men tend to present late with mass effect symptoms, although symptoms of hypogonadism (decreased libido, impotence, infertility, hot flashes, decreased muscle strength, and gynecomastia) may have been present for many years. Diagnostic tests show significantly elevated prolactin levels at least five times above normal which usually parallel the size of the tumor [18]. Decreased bone strength and increased risk for fracture is a longterm complication of untreated hypogonadism in both genders. Presence of a pituitary mass is suspected based on mass effect symptoms or endocrine abnormalities. Knowledge of the anatomy of the region is important to understanding the mass effect symptoms caused by pituitary tumors. The pituitary gland is located in the sella turcica, immediately superior to the sphenoid sinus, and is connected to the hypothalamus by the infundibulum or stalk. Endocrine abnormalities may be hypersecretion functioning pituitary adenomas or various degrees of anterior pituitary hormone deficits with pituitary macroadenomas. Posterior pituitary gland deficits like diabetes insipidus are not typical clinical manifestations of pituitary adenomas. Diabetes insipidus may occur with craniopharyngiomas or tumors that infiltrate the infundibulum. Evaluation by an endocrinologist is essential Pituitary Tumors 545 phenotypical changes (acral enlargement, facial and teeth changes), increased sweating, arthralgias, headaches, hypertension, glucose intolerance, carpal tunnel syndrome, hypogonadism, and sleep apnea. Although phenotypical changes can be pronounced, acromegaly has a slow progressive course and diagnosis is usually made almost 10 years after onset of manifestations. Other biochemical abnormalities in patients with acromegaly may include hyperprolactinemia (as a result of a cosecreting tumor that secretes prolactin or due to stalk effect) and central hypogonadism. Patients with Cushing syndrome present with centripetal weight gain (abdominal, supraclavicular and dorsocervical fat accumulation), skin changes (dark striae, easy bruising, hirsutism), proximal muscle weakness, hypertension, hypogonadism, and impaired glucose tolerance. The longterm consequences of untreated hypercortisolemia (accelerated atherosclerosis, opportunistic infections, deep vein thromboses, and bone fractures) are devastating and lead to increased mortality. Differential diagnosis includes reactive hypercortisolemia (or pseudoCushing) that occurs in patients with psychiatric conditions (depression, anxiety, anorexia nervosa, and obsessive compulsive disorder), uncontrolled diabetes mellitus, chronic alcoholism, and morbid obesity. The biochemical diagnosis of Cushing syndrome includes a combination of screening tests: bedtime salivary cortisol measurements, 24hour urinary cortisol levels, and lowdose dexamethasone suppression tests [21,22]. The main differential diagnosis is the syndrome of resistance to thyroid hormone, which is usually associated with a family history of thyroid disease. Measurement of alpha subunit is helpful in making the diagnosis, as are dynamic endocrine and genetic testing [25]. The diagnosis of functioning gonadotropinoma in men is suggested by elevated gonadotroph level, alpha subunit, and testosterone. Craniopharyngiomas present with mass effect symptoms, diabetes insipidus, and multiple anterior pituitary hormone deficiencies. Due to their suprasellar location, they may cause hypothalamic syndrome with increased appetite, morbid obesity, and sleep dysregulation. As many craniopharyngiomas present in childhood, linear growth and sexual development are often affected. Treatment General Considerations Pituitary tumors are best treated in tertiary referral centers by multidisciplinary collaboration between experienced neurosurgeons, endocrinologists, and radiation oncologists. Surgical resection of pituitary adenomas is almost exclusively done by the transsphenoidal approach, while staged or combined transsphenoidal­transcranial approaches are used for giant tumors with large temporal suprasellar components, especially dumbbell configuration. Most recently, threedimensional endoscopic pituitary surgery is being used in some centers as it provides improved depth perception [26]. The floor of the sella is often thinned considerably by the tumor within the sella.

Metastases are identified in at least 10% of cases at the time of diagnosis [95] and are associated with a poor prognosis impotence zargan vivanza 20 mg buy low cost. The clinical presentation is hematuria with or without lower urinary tract symptoms xylitol erectile dysfunction order vivanza from india. For muscle invasion erectile dysfunction treatment las vegas 20 mg vivanza purchase mastercard, radical cystectomy remains the most effective treatment option where the 5year survival rate ranges between 23 and 48% [96] injections for erectile dysfunction cost buy vivanza. Some recommend routine urethrectomy along with radical cystectomy erectile dysfunction acupuncture generic vivanza 20 mg with visa, as urethral recurrence rates are reported to be as high as 40%. Radiotherapy failed to be effective as sole therapy with a reported 5year survival rate of 5­18%. As for chemotherapy, some studies showed promising results with the adjuvant use of agents such as epirubicin, with a 50­60% response rate being observed in patients with locally advanced and metastatic disease [90]. In cases of advanced disease with nodal or distant metastases, palliative chemotherapy or radiation therapy is used. Most affected patients are in the fifth and sixth decade of life, and males are three times more likely to be affected than females [93]. Cases have also been related to pelvic irradiation and occupational chemical exposure [99]. Metastases most commonly involve the liver, brain, lung, bone, and lymph nodes [100]. Due to the low incidence and the late presentation of the disease, only small retrospective studies are available. Transurethral resection of the bladder tumor as the sole treatment modality is not favored because the tumor is usually muscle invasive with poor 3­6 month survival rates [100]. Cystectomy alone is also usually not curative because of the high rate of systemic recurrence. This prompted the use of neoadjuvant chemotherapy or chemoradiotherapy with bladdersparing protocols [101]. The most commonly used regimens are cisplatin and etoposide, carboplatin and etoposide, and cyclophosphamide, doxorubicin, and vincristine [97]. The health economics of bladder cancer: a comprehensive review of the published literature. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a metaanalysis of epidemiologic studies. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Elevated bladder cancer in northern New England: the role of drinking water and arsenic. A casecontrol study of smoking and bladder cancer risk: emergent patterns over time. Smoking status is a risk factor for recurrence after transurethral resection of non muscleinvasive bladder cancer. Analgesic and antiinflammatory drug use and risk of bladder cancer: a population based case control study. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Do mixed histological features affect survival benefit from neoadjuvant platinum based combination chemotherapy in patients with locally advanced bladder cancer A secondary analysis of Southwest Oncology GroupDirected Intergroup Study (S8710). Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. Pathological response to neoadjuvant chemotherapy for muscleinvasive micropapillary bladder cancer. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/ computed tomography for staging of muscleinvasive bladder carcinoma. Photodynamic diagnosis of nonmuscleinvasive bladder cancer with hexaminolevulinate cystoscopy: a metaanalysis of detection and recurrence based on raw data. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on nonmuscle invasive bladder cancer recurrence. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscleinvasive bladder tumors­results of a prospective, randomized comparison to the standard approach. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. Cost effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. Use of fluorescence in situ hybridization to predict response to bacillus Calmette Guerin therapy for bladder cancer: results of a prospective trial. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with highrisk superficial bladder tumours undergoing intravesical therapy. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. Impact of routine second transurethral resection on the longterm outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and diseasespecific survival: a prospective randomised clinical trial. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus CalmetteGuerin therapy. An individual patient data metaanalysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus CalmetteGuerin for non muscleinvasive bladder cancer. Intravesical bacillus CalmetteGuerin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy Prognosis of muscleinvasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Impact of previous bacille CalmetteGuerin failure pattern on subsequent 53 54 55 56 57 58 59 60 61 62 63 64 65 66 response to bacille CalmetteGuerin plus interferon intravesical therapy. Gemcitabine versus bacille CalmetteGuerin after initial bacille Calmette Guerin failure in nonmuscleinvasive bladder cancer: a multicenter prospective randomized trial. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End ResultsMedicare analysis. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancerspecific survival in patients with lymph nodenegative urothelial carcinoma of the bladder undergoing radical cystectomy. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1,054 patients. Factors influencing postrecurrence survival in bladder cancer following radical cystectomy. Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Longterm survival in metastatic transitionalcell carcinoma and prognostic factors predicting outcome of therapy. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a singlearm, multicentre, phase 2 trial. Family history of cancer among cases of upper urothelial tumours in a Balkan nephropathy area. Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Tumors of the urinary bladder: a clinico pathological analysis of over 2500 specimens and biopsies. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5fluorouracil, doxorubicin, and mitomycinC. Urachal carcinoma: clinicopathologic features and longterm outcomes of an aggressive malignancy. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: a contemporary review with focus on nonbilharzial squamous cell carcinoma. Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus CalmetteGuerin. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Small cell carcinoma of the urinary bladder: a rare, aggressive neuroendocrine malignancy. Small cell carcinoma of the urinary bladder: a 15year retrospective review of treatment and survival in the Anglian Cancer Network. Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. Five broad categories of ovarian cancers exist: epithelial, germ cell, sex cord­stromal, nonspecific mesenchymal tumors, and metastases. Additionally, fallopian tube and primary peritoneal carcinomas share similar histology, patterns of spread, and treatment modalities as epithelial ovarian cancer and are therefore often considered together in discussions of ovarian cancer. The purpose of this chapter is to discuss the incidence, mortality, risk factors, and the role of screening and early detection of all types of ovarian cancer. Following this, a detailed discussion on epithelial ovarian cancer, including clinical presentation, surgical management, and systemic chemotherapy is included. Finally, germ cell and sex cord­stromal tumors, the most common of the rarer ovarian cancers are discussed in brief. These data concerning cases, deaths, incidence and mortality rates, and survival consider ovarian cancer overall, but largely reflect the predominant forms of epithelial ovarian cancers. Fallopian tube cancer has traditionally been thought to be very rare (<1% of all gynecologic cancers). However, increasing evidence suggests that many serous ovarian cancers originate in the fimbriated end of the fallopian tube. Reproductive Factors the most strongly associated risk factors for the development of epithelial ovarian and fallopian tube cancers are prior reproductive history and length of reproductive years. Early age at menarche and late age at menopause, as well as nulliparity and infertility, increase the risk of epithelial ovarian cancer, which is thought to be secondary to incessant ovulation [5]. Conversely, those factors that reduce the number of lifetime ovulations are thought to be protective. The ageadjusted incidence and mortality rates, based on data from 2009 to 2013, is 11. Breastfeeding for more than 18 months also confers some protection against epithelial ovarian cancer with a 2% decreased relative risk with each month of breastfeeding [8]. Obesity One large Norwegian study found that women who were obese in adolescence and childhood had a relative risk of 1. This finding was confirmed in a metaanalysis of 28 studies which showed an odds ratio of 1. These results can be used to inform discussions between physicians and their patients. In addition, endometriosis is well established as a risk factor for ovarian cancers of endometrioid and clear cell histologies. Risk Factors for Ovarian Stromal and Germ Cell Tumors While germ cell tumors comprise less than 5% of all ovarian cancers in Western countries, they represent up to 15% of ovarian cancers in Asia. Younger age is a risk factor for germ cell tumors which are rare after the third decade of life. However, a significant reduction in mortality was noted in the group randomized to multimodal screening when prevalent cases were excluded. Further follow up and research is needed to confirm these findings and evaluate the costeffectiveness of multimodal ovarian cancer screening [15]. This test may be useful, in conjunction with a standard preoperative evaluation and clinical impression, for nongynecologic oncology providers in assessing when a patient with an adnexal mass should be referred to a gynecologic oncologist for further management prior to surgical intervention, although the cost­benefit of this expensive test should be part of the decisionmaking process [19]. While the above research is promising, no screening test or combination of tests has yet shown sufficient sensitivity/specificity and/or survival benefit to be routinely recommended for the general population currently [20]. Screening and Early Detection Advanced stage at diagnosis and high mortality in ovarian, fallopian tube, and primary peritoneal cancers are due to a lack of effective screening tests for the general population.

Buy vivanza 20 mg mastercard. Pastilla amarilla para hombres - Tadalafil | Indicaciones y riesgos | Erección disfunción Eréctil.

References

• Kiely, E.A., Ryan, P.C., McErmott, T.E. et al. Piezoelectric lithotripsy: experience with 511 patients. In: Lingeman, J.E., Newman, D.M., eds. Shockwave Lithotripsy1.
• Ruth Porter (Editor), Julie Knight (Editor). In High Altitude Physiology: Cardiac and Respiratory aspects. CIBA Foundation. 1971.
• Gallo SH, McClave SA, Makk LJ, et al: Standardization of clinical criteria required for use of the 12.
• Kolettis PN, Klein EA, Novick AC, et al: The Le Bag orthotopic urinary diversion, J Urol 156(3):926n930, 1996.
• Dietrich CF, Sahai AV, D'Onofrio M, et al. Differential diagnosis of small solid pancreatic lesions. Gastrointest Endosc. 2016;84(6):933-940.
• Tobin MJ: Advances in mechanical ventilation. N Engl J Med 344:1986-1996, 2001.